Integra LifeSciences Holdings Corporation

NasdaqGS:IART Voorraadrapport

Marktkapitalisatie: US$1.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Integra LifeSciences Holdings Beheer

Beheer criteriumcontroles 4/4

Integra LifeSciences Holdings' CEO is Jan De Witte, appointed in Dec 2021, has a tenure of 2.83 years. total yearly compensation is $6.39M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $333.39K. The average tenure of the management team and the board of directors is 3.5 years and 11.4 years respectively.

Belangrijke informatie

Jan De Witte

Algemeen directeur

US$6.4m

Totale compensatie

Percentage CEO-salaris13.7%
Dienstverband CEO2.8yrs
Eigendom CEO0.02%
Management gemiddelde ambtstermijn3.5yrs
Gemiddelde ambtstermijn bestuur11.4yrs

Recente managementupdates

Recent updates

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08
Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Oct 19
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Analyse CEO-vergoeding

Hoe is Jan De Witte's beloning veranderd ten opzichte van Integra LifeSciences Holdings's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$24m

Mar 31 2024n/an/a

US$40m

Dec 31 2023US$6mUS$875k

US$68m

Sep 30 2023n/an/a

US$101m

Jun 30 2023n/an/a

US$131m

Mar 31 2023n/an/a

US$172m

Dec 31 2022US$9mUS$850k

US$181m

Sep 30 2022n/an/a

US$173m

Jun 30 2022n/an/a

US$166m

Mar 31 2022n/an/a

US$157m

Dec 31 2021US$899kUS$59k

US$169m

Compensatie versus markt: Jan's total compensation ($USD6.39M) is about average for companies of similar size in the US market ($USD5.54M).

Compensatie versus inkomsten: Jan's compensation has been consistent with company performance over the past year.


CEO

Jan De Witte (60 yo)

2.8yrs

Tenure

US$6,388,756

Compensatie

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Stuart Essig
Executive Chairman26.8yrsUS$422.52k2.26%
$ 31.9m
Jan De Witte
President2.8yrsUS$6.39m0.024%
$ 333.4k
Lea Knight
Executive VP & CFO1.3yrsUS$1.67m0.054%
$ 761.9k
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer7yrsUS$1.25m0.047%
$ 655.8k
Eric Schwartz
Executive VP5.9yrsUS$1.62m0.082%
$ 1.2m
Robert Davis
Executive VP & President of Tissue Technologies11.8yrsUS$1.42m0.084%
$ 1.2m
Michael McBreen
Executive VP & President of Codman Specialty Surgical4.4yrsUS$2.83m0.075%
$ 1.1m
Stephen Leonard
Corporate VP of Global Operations & Supply Chain4.2yrsgeen gegevensgeen gegevens
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno datageen gegevensgeen gegevens
Ruth Fleming
Vice President of Global Marketingno datageen gegevensgeen gegevens
Chantal Veillon-Berteloot
Executive VP & Chief Human Resources Officer1.8yrsgeen gegevens0.031%
$ 442.9k
Mark Jesser
Corporate VP & Chief Digital Officer2.8yrsgeen gegevensgeen gegevens

3.5yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: IART's management team is considered experienced (3.5 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Stuart Essig
Executive Chairman26.8yrsUS$422.52k2.26%
$ 31.9m
Jan De Witte
President2.8yrsUS$6.39m0.024%
$ 333.4k
Raymond Murphy
Independent Director15.5yrsUS$297.54k0.11%
$ 1.5m
Christian Schade
Independent Director18.8yrsUS$293.28k0.082%
$ 1.2m
Barbara Hill
Independent Presiding Director11.4yrsUS$342.54k0.18%
$ 2.5m
Keith N. Bradley
Independent Director32.8yrsUS$306.31k0.090%
$ 1.3m
Jeffrey Graves
Independent Directorless than a yearUS$90.68k0.016%
$ 227.0k
Shaundra Clay
Independent Director3.5yrsUS$260.04k0.028%
$ 398.4k
Renee Lo
Independent Director2.3yrsUS$297.54k0.021%
$ 293.5k

11.4yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: IART's board of directors are seasoned and experienced ( 11.4 years average tenure).